1[1]Antithrombotic Trialists'Collaboration.Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients[J].BMJ,2002,324:71-86.
3[3]Haubelt H,Anders C,Hellstern P.Can platelet function tests predict the clinical efficacy of aspirin[J].Semin Thromb Hemost,2005,31(4):404-410.
4[4]Sane DC,McKee SA,Malinin AI,et al.Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin[J].Am J Cardiol,2002,90(8):893-895.
5[5]Zhou L,Schmaier AH.Platelet aggregation testing in platelet-rich plasma:description of procedures with the aim to develop standards in the field[J].Am J Clin Pathol,2005,123:172-183.
6[6]Moffat KA,Ledford-Kraemer MR,Nichols WL,et al.Variability in clinical laboratory practice in testing for disorders of platelet function:results of two surveys of the North American Specialized Coagulation Laboratory Association[J].Thromb Haemost,2005,93:549-553.
7[7]Harrison P.The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults[J].Br J Haematol,2005,130:3-10.
8[8]Grundmann K,Jaschonek K,Kleine B,et al.Aspirin non-responder status in patients with recurrent cerebral ischemic attacks[J].J Neurol,2003,250(1):63-66.
9[9]Fuchs I,Frossard M,Spiel A,et al.Platelet hyperfunction and low response to aspirin predict re-events in patients with acute coronary syndromes during long term follow up[J].J Thromb Haemost,2005,3(supplement 1):2142.
10[10]Christie DJ,Kottke-Marchant K,Gorman R.High shear platelet function is associated with major adverse events in patients with Stable cardiovascular disease (CVD)despite aspirin therapy[J].J Thromb Haemost,2005,3(supplement1):2204.
